Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
5(42%)
Results Posted
20%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
7
58%
Ph phase_1
5
42%

Phase Distribution

5

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
7(58.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

5

trials recruiting

Total Trials

12

all time

Status Distribution
Active(5)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Recruiting3
Active, not recruiting2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
5
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (41.7%)
Phase 27 (58.3%)

Trials by Status

terminated18%
unknown18%
completed542%
recruiting325%
active_not_recruiting217%

Recent Activity

5 active trials
Showing 5 of 12
recruitingphase_2

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

NCT06835387
recruitingphase_2

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941
active_not_recruitingphase_2

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

NCT04005339
completedphase_2

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04752696
recruitingphase_2

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

NCT05472259
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06835387Phase 2

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Recruiting
NCT06219941Phase 2

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Recruiting
NCT04005339Phase 2

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Active Not Recruiting
NCT04752696Phase 2

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Completed
NCT05472259Phase 2

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Recruiting
NCT03368963Phase 1

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Active Not Recruiting
NCT03810742Phase 1

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Completed
NCT05363007Phase 2

Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma

Unknown
NCT02022644Phase 1

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

Completed
NCT03712397Phase 2

Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy

Completed
NCT03119064Phase 1

BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma

Terminated
NCT04088786Phase 1

Phase I Trial HIPEC With Nal-irinotecan

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12